Observations regarding the immunogenicity of BDD-rFVIII derived from a mechanistic personalized medicine perspective

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 9, 2012, Pages 1961-1965

  Sauna, Z E ^a   Ameri, A ^b   Kim, B ^c   Yanover, C ^d   Viel, K R ^e   Rajalingam, R ^f   Cole, S A ^g   Howard, T E ^f,h,i  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e Histonis Inc   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^h VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B DOMAIN DELETED RECOMBINANT BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; DRUG PROTEIN BINDING; DRUG STRUCTURE; IMMUNE RESPONSE; IMMUNOGENICITY; LETTER; PRIORITY JOURNAL; PROTEIN ENGINEERING;

AMINO ACID SEQUENCE; FACTOR VIII; HUMANS; INDIVIDUALIZED MEDICINE; RECOMBINANT PROTEINS; SEQUENCE DELETION;

EID: 84865790103     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04830.x     Document Type: Letter

References (17)

1. Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies J Thromb Haemost 2011; 9: 2180-92.
2. Iorio A, Marcucci M, Makris M. Concentrate-related inhibitor risk: is a difference always real? J Thromb Haemost 2011; 9: 2176-9.
3. Bray GL, Kroner BL, Arkin S, Aledort LW, Hilgartner MW, Eyster ME, Ragni MV, Goedert JJ. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study. Am J Hematol 1993; 42: 375-9.
4. Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000; 95: 1324-9.
5. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-5.
6. Howard TE, Yanover C, Mahlangu J, Krause A, Viel KR, Kasper CK, Pratt KP. Haemophilia management: time to get personal? Haemophilia 2011; 17: 721-8.
7. Kelley B, Jankowski M, Booth J. An improved manufacturing process for Xyntha/ReFacto AF. BDD-FVIII in CHO cells and same primary amino acid sequence. Haemophilia 2010; 16: 717-25.
8. Lind P, Larsson K, Spira J, Sydow-Bäckman M, Almstedt A, Gray E, Sandberg H. Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization. Eur J Biochem 1995; 232: 19-27.
9. Sandberg H, Almstedt A, Brandt J, Gray E, Holmquist L, Oswaldsson U, Sebring S, Mikaelsson M. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ. Thromb Haemost 2001; 85: 93-100.
10. Pruitt KD, Harrow J, Harte RA, Wallin C, Diekhans M, Maglott DR, Searle S, Farrell CM, Loveland JE, Ruef BJ, Hart E, Suner MM, Landrum MJ, Aken B, Ayling S, Baertsch R, Fernandez-Banet J, Cherry JL, Curwen V, Dicuccio M, et al. The consensus coding sequence (CCDS) project: Identifying a common protein-coding gene set for the human and mouse genomes. Genome Res 2009; 19: 1316-23.
11. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005; 23: 975-1028.
12. Jacquemin M, Vantomme V, Buhot C, Lavend'homme R, Burny W, Demotte N, Chaux P, Peerlinck K, Vermylen J, Maillere B, van der Bruggen P, Saint-Remy JM. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 2003; 101: 1351-8.
13. Nielsen M, Lundegaard C, Blicher T, Peters B, Sette A, Justesen S, Buus S, Lund O. Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan. PLoS Comput Biol 2008; 4: e1000107.
14. Lippolis JD, White FM, Marto JA, Luckey CJ, Bullock TNJ, Shabanowitz J, Hunt DF, Engelhard VH. Analysis of MHC Class II antigen processing by quantitation of peptides that constitute nested sets. J Immunol 2002; 169: 5089-97.
15. Wang P, Sidney J, Dow C, Mothe′ B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 2008; 4: e1000048.
16. Yanover C, Jain N, Pierce G, Howard TE, Sauna ZE. Pharmacogenetics and the immunogenicity of protein therapeutics. Nat Biotechnol 2011; 29: 870-3.
17. Viel KR, Ameri A, Abshire TC, Iyer RV, Watts RG, Lutcher C, Channell C, Cole SA, Fernstrom KM, Nakaya S, Kasper CK, Thompson AR, Almasy L, Howard TE. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009; 360: 1618-27.